HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection.

Abstract
Although treatment for heart failure induced by cancer therapy has improved in recent years, the prevalence of cardiomyopathy due to antineoplastic therapy remains significant worldwide. In addition to traditional mediators of myocardial damage, such as reactive oxygen species, new pathways and target cells should be considered responsible for the impairment of cardiac function during anticancer treatment. Accordingly, there is a need to develop novel therapeutic strategies to protect the heart from pharmacologic injury, and improve clinical outcomes in cancer patients. The development of novel protective therapies requires testing putative therapeutic strategies in appropriate animal models of chemotherapy-induced cardiomyopathy. This Position Paper of the Working Group on Drug Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology aims to: (1) define the distinctive etiopatogenetic features of cardiac toxicity induced by cancer therapy in humans, which include new aspects of mitochondrial function and oxidative stress, neuregulin-1 modulation through the ErbB receptor family, angiogenesis inhibition, and cardiac stem cell depletion and/or dysfunction; (2) review the new, more promising therapeutic strategies for cardioprotection, aimed to increase the survival of patients with severe antineoplastic-induced cardiotoxicity; (3) recommend the distinctive pathological features of cardiotoxicity induced by cancer therapy in humans that should be present in animal models used to identify or to test new cardioprotective therapies.
AuthorsRosalinda Madonna, Christian Cadeddu, Martino Deidda, Donato Mele, Ines Monte, Giuseppina Novo, Pasquale Pagliaro, Alessia Pepe, Paolo Spallarossa, Carlo Gabriele Tocchetti, Concetta Zito, Giuseppe Mercuro
JournalHeart failure reviews (Heart Fail Rev) Vol. 20 Issue 5 Pg. 621-31 (Sep 2015) ISSN: 1573-7322 [Electronic] United States
PMID26168714 (Publication Type: Guideline, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Cardiotonic Agents
  • NRG1 protein, human
  • Neuregulin-1
Topics
  • Animals
  • Antineoplastic Agents (adverse effects)
  • Cardiotonic Agents (pharmacology)
  • Cardiotoxicity (etiology, metabolism, prevention & control)
  • Disease Models, Animal
  • Humans
  • Mitochondria, Heart (drug effects, physiology)
  • Neoplasms (drug therapy)
  • Neuregulin-1 (metabolism)
  • Oxidative Stress (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: